JP2017503810A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503810A5 JP2017503810A5 JP2016545917A JP2016545917A JP2017503810A5 JP 2017503810 A5 JP2017503810 A5 JP 2017503810A5 JP 2016545917 A JP2016545917 A JP 2016545917A JP 2016545917 A JP2016545917 A JP 2016545917A JP 2017503810 A5 JP2017503810 A5 JP 2017503810A5
- Authority
- JP
- Japan
- Prior art keywords
- ectodomain
- ntb
- subject
- cell
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims 27
- 102100029197 SLAM family member 6 Human genes 0.000 claims 19
- 239000000556 agonist Substances 0.000 claims 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 10
- 102000046571 human SLAMF6 Human genes 0.000 claims 8
- 206010033661 Pancytopenia Diseases 0.000 claims 7
- 208000024389 cytopenia Diseases 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 5
- 108091008874 T cell receptors Proteins 0.000 claims 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 5
- 238000011534 incubation Methods 0.000 claims 5
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000002627 4-1BB Ligand Human genes 0.000 claims 3
- 108010082808 4-1BB Ligand Proteins 0.000 claims 3
- 230000000638 stimulation Effects 0.000 claims 3
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 2
- 208000033779 X-linked lymphoproliferative disease Diseases 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 239000004606 Fillers/Extenders Substances 0.000 claims 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 claims 1
- 206010025327 Lymphopenia Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000050327 human TNFRSF9 Human genes 0.000 claims 1
- 102000051144 human TNFSF9 Human genes 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 231100001023 lymphopenia Toxicity 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925265P | 2014-01-09 | 2014-01-09 | |
| US61/925,265 | 2014-01-09 | ||
| PCT/IL2015/050033 WO2015104711A1 (en) | 2014-01-09 | 2015-01-08 | Improved cell compositions and methods for cancer therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020053791A Division JP7004761B2 (ja) | 2014-01-09 | 2020-03-25 | 癌治療のための改善された細胞組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503810A JP2017503810A (ja) | 2017-02-02 |
| JP2017503810A5 true JP2017503810A5 (enExample) | 2018-02-22 |
| JP6682438B2 JP6682438B2 (ja) | 2020-04-15 |
Family
ID=53523593
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016545917A Active JP6682438B2 (ja) | 2014-01-09 | 2015-01-08 | 癌治療のための改善された細胞組成物および方法 |
| JP2020053791A Active JP7004761B2 (ja) | 2014-01-09 | 2020-03-25 | 癌治療のための改善された細胞組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020053791A Active JP7004761B2 (ja) | 2014-01-09 | 2020-03-25 | 癌治療のための改善された細胞組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10344073B2 (enExample) |
| EP (2) | EP4101461A1 (enExample) |
| JP (2) | JP6682438B2 (enExample) |
| AU (1) | AU2015205327B2 (enExample) |
| CA (1) | CA2935903A1 (enExample) |
| ES (1) | ES2902835T3 (enExample) |
| IL (1) | IL246607B (enExample) |
| WO (1) | WO2015104711A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018098401A1 (en) * | 2016-11-23 | 2018-05-31 | Translational Drug Development, Llc | Benzamide and active compound compositions and methods of use |
| CN107502589A (zh) * | 2017-08-04 | 2017-12-22 | 北京世纪劲得生物技术有限公司 | 一种肿瘤浸润淋巴细胞与单个核细胞共培养方法 |
| US11110171B2 (en) | 2017-12-21 | 2021-09-07 | New York University | PD-1 related cancer therapy |
| US12455279B2 (en) | 2018-01-25 | 2025-10-28 | Mia Levite | Personalized immunotherapy for rejuvenating activating and strengthening exhausted and dysfunctional T cells, reducing PD-1, and improving immune function |
| JP7458318B2 (ja) * | 2018-02-12 | 2024-03-29 | ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド | 癌治療のためのｓｌａｍｆ６スプライスバリアントの調節 |
| IL267614A (en) * | 2019-06-24 | 2019-09-26 | Lotem Michal | Nucleic acids to modulate SLAMF6 isoforms |
| WO2021001653A1 (en) | 2019-07-03 | 2021-01-07 | Oxford Biotherapeutics Ltd | Antibodies and methods of use |
| CA3179702A1 (en) | 2020-05-05 | 2021-11-11 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| CA3179700A1 (en) | 2020-05-05 | 2021-11-11 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| IL311444A (en) | 2021-10-01 | 2024-05-01 | Nuvalent Inc | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US7479269B2 (en) * | 1988-11-23 | 2009-01-20 | Genetics Institute, Llc | Methods for selectively enriching TH1 and TH2 cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5719867A (en) | 1995-06-30 | 1998-02-17 | Scientific-Atlanta, Inc. | Plural telephony channel baseband signal demodulator for a broadband communications system |
| US6284267B1 (en) | 1996-08-14 | 2001-09-04 | Nutrimed Biotech | Amphiphilic materials and liposome formulations thereof |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| WO2001079444A2 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc | Albumin fusion proteins |
| US20050054051A1 (en) | 2001-04-12 | 2005-03-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2454185A1 (en) | 2001-07-19 | 2003-01-30 | Innate Pharma | Ntb-a, a surface molecule involved in natural killer cells activity |
| MXPA04001986A (es) * | 2001-08-29 | 2004-06-07 | Genentech Inc | Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad. |
| US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| JP2005206478A (ja) | 2004-01-20 | 2005-08-04 | Kirin Brewery Co Ltd | 樹状細胞膜分子−ＩｇＦｃ融合ポリペプチドまたはそれに対する抗体を含む医薬組成物 |
| US7592313B2 (en) * | 2004-05-17 | 2009-09-22 | Board Of Trustees Of The University Of Illinois | Method of stimulating proliferation of regulatory T cells in a diabetic mammal |
| ES2319286T3 (es) | 2004-10-02 | 2009-05-06 | Immatics Biotechnologies Gmbh | Epitopos inmunogenos de linfocitos t colaboradores de antigenos de tumor humanos y utilizacion de dichos epitopos en metodos inmunoterapeuticos. |
| EP1871911A2 (en) | 2005-04-07 | 2008-01-02 | Chiron Corporation | Cancer-related genes (prlr) |
| EP1916302A4 (en) * | 2005-08-17 | 2009-10-21 | Takara Bio Inc | PROCESS FOR THE PRODUCTION OF LYMPHOCYTES |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| TW200823237A (en) | 2006-08-28 | 2008-06-01 | Nuvelo Inc | Antibodies to NTB-A |
| WO2009065065A1 (en) | 2007-11-15 | 2009-05-22 | Ceramoptec Industries, Inc. | Pegylated liposomal formulations for photodynamic treatment of inflammatory diseases |
| WO2012129201A1 (en) * | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| IL267614A (en) | 2019-06-24 | 2019-09-26 | Lotem Michal | Nucleic acids to modulate SLAMF6 isoforms |
-
2015
- 2015-01-08 AU AU2015205327A patent/AU2015205327B2/en active Active
- 2015-01-08 WO PCT/IL2015/050033 patent/WO2015104711A1/en not_active Ceased
- 2015-01-08 US US15/110,111 patent/US10344073B2/en active Active
- 2015-01-08 JP JP2016545917A patent/JP6682438B2/ja active Active
- 2015-01-08 EP EP21197303.7A patent/EP4101461A1/en active Pending
- 2015-01-08 ES ES15734922T patent/ES2902835T3/es active Active
- 2015-01-08 CA CA2935903A patent/CA2935903A1/en active Pending
- 2015-01-08 EP EP15734922.6A patent/EP3091999B2/en active Active
-
2016
- 2016-07-05 IL IL246607A patent/IL246607B/en unknown
-
2019
- 2019-05-20 US US16/417,048 patent/US11530251B2/en active Active
-
2020
- 2020-03-25 JP JP2020053791A patent/JP7004761B2/ja active Active
-
2022
- 2022-11-10 US US18/054,346 patent/US20230078665A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503810A5 (enExample) | ||
| Chalan et al. | Thyroid dysfunctions secondary to cancer immunotherapy | |
| Liang et al. | Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell–mediated killing | |
| Kanagavelu et al. | In vivo effects of lattice radiation therapy on local and distant lung cancer: potential role of immunomodulation | |
| EP2100615B1 (en) | Cancer therapy | |
| JP6899333B2 (ja) | 汎用キラーｔ細胞 | |
| Chang et al. | Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors | |
| Spaas et al. | Is the combination of immunotherapy and radiotherapy in non-small cell lung cancer a feasible and effective approach? | |
| Lian et al. | Induction of an effective anti-tumor immune response and tumor regression by combined administration of IL-18 and Apoptin | |
| US10016421B2 (en) | Histone deacetylase 6 inhibition for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination | |
| Reijmen et al. | Fractionated radiation severely reduces the number of CD8+ T cells and mature antigen presenting cells within lung tumors | |
| Plavc et al. | Combining radiotherapy and immunotherapy in definitive treatment of head and neck squamous cell carcinoma: review of current clinical trials | |
| Catani et al. | Intratumoral immunization by p19Arf and interferon-β gene transfer in a heterotopic mouse model of lung carcinoma | |
| Lin et al. | (−)-4-o-(4-O-β-D-glucopyranosylcaffeoyl) quinic acid inhibits the function of myeloid-derived suppressor cells to enhance the efficacy of anti-PD1 against colon cancer | |
| Pan et al. | Synthesized natural peptides from amphibian skin secretions increase the efficacy of a therapeutic vaccine by recruiting more T cells to the tumour site | |
| TWI759270B (zh) | 藉由t細胞療法治療多發性骨髓瘤及漿細胞白血病之方法 | |
| WO2020163782A2 (en) | Immunotherapy for the treatment and prevention of inflammatory bowel disease | |
| Ludwig et al. | Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma | |
| Suginobe et al. | Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors | |
| CN103097398B (zh) | 免疫原性肽以及包含该肽的用于预防或治疗hpv相关疾病的组合物 | |
| Gewirtz et al. | The potentially conflicting cell autonomous and cell non-autonomous functions of autophagy in mediating tumor response to cancer therapy | |
| CN108524918B (zh) | 一种抗肿瘤组合物及其表达载体和应用 | |
| Hao et al. | Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors | |
| Cayssials et al. | Beyond tyrosine kinase inhibitors: Combinations and other agents | |
| EP3717013A1 (en) | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |